Company Update Q3 2025 Unaudited Results (29-October-2025)

Oct 2025

PT Kalbe Farma Tbk (KLBF IJ/KLBF.JK)

1 1

YTD Sep 2025

Forward-Looking Statement

This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. ("Kalbe" or the "Company"). This presentation has been prepared solely for use in connection with the release of 30 September 2025 unaudited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation.

The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person. This presentation does not constitute a recommendation regarding the securities of the Company. This presentation, including the information and opinions contained herein, is provided as of the date of this presentation and is subject to change without notice, including change as a result of the issuance of 30 September 2025 unaudited results of the Company.

This presentation includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", estimate", "expect" and words of similar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans, objectives relating to the Company's products and services and anticipated product launches) are forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this presentation. The Company expressly disclaims any obligation or reflection of any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any statement is based. Market data and certain industry forecasts used in this presentation were obtained from market research, publicly available information and industry publications which have not been independently verified, and no representation is made as to the accuracy of such information.

2

• Key Updates 04

• Business Strategies 10

• Financial Overview 25

• Appendix 1 32

• Appendix 2 39

3

4

Corporate Overview

Net Sales

IDR 26.0 tn

7%

International

93%

Domestic

33.4%

Distribution &

Logistics

23.3%

Nutritionals

29.5%

Prescription Pharmaceuticals

13.8%

Consumer Health

Market Capitalization*

IDR 52.90 tn | USD 3.17 bn

*As of 30 SepTember '25

Free Float*

Treasury Shares*

Establishment

IDX Listed

Free FloaT is calculaTed as ToTal shares deducTed by The majoriTy, affiliaTed boards, Treasury shares and scripT shares 5

Key Takeaways

7.2% 10.6%

net sales growth

Key Updates

Positive organic top-line growth driven by volume

Margin improvement Marketing investment to sustain growth

Progressing on track in key projects to drive future growth

net profit growth

Key Risks

Pressure on purchasing power in domestic market Exchange rate fluctuation amidst geopolitics and trade war

Focusing on Total Shareholder Return

• Strong fundamentals

• Healthy cash flow generation allows improving dividend policy while investing for future growth

• Strengthening product portfolio through collaboration

• Established JV Livzon Pharma Indonesia to manufacture pharmaceuticals ingredients

  Strategic Partnerships and Investments

• Zerpidio and Efesa

  commercialization

• Strategic Partnership with Alliance Pharma Co.,Ltd. (Thailand)

  • Radiopharmaceuticals facilities (cyclotron) • Medical devices currently on progress

6

2025 Key Strategies

Investing for long term growth through innovation and collaboration

Distribution & Logistics

• Deepening penetration in selected countries

• Optimizing Alliance Pharma to bring biologics

product to Thai market

• New potential principals

• Strengthening medical and distribution channel

• Rejuvenating our brands to drive competitive advantage

• Expanding into preventive category

• Strengthening nutritionals presence in affordable and lifestyle categories

7

Key updates

Business Strategy

Financial Updates

Appendix I

Appendix II

8

9

‌Prescription Pharmaceuticals

Key updates

Business Strategy

Financial Updates

Appendix I

Appendix II

Growing specialty category by commercialization and expansion of innovative portfolio, supported by local manufacturing

Consistent growth in E-Catalog

by leveraging on strong commercial team and distribution network

10